Mark Laughlin
Impact in
- Virology top 0.5%
- HIV Research and Treatment
- Infectious Diseases top 1%
- Antifungal resistance and susceptibility
- HIV/AIDS drug development and treatment
Papers in
-
- Antifungal resistance and susceptibility 6
- HIV/AIDS Research and Interventions 5
- Virology 10
- HIV Research and Treatment 10
- Co-authors
- Josephine Lim (6 shared papers)Rachel Courtney (4 shared papers)Francisco González‐Scarano (7 shared papers)Janet M. Harouse (5 shared papers)David Wexler (3 shared papers)Elaine Radwanski (2 shared papers)Shama Bhat (1 shared paper)Steven L. Spitalnik (1 shared paper)
- Journals
- Alzheimer s & Dementia (5 papers)Antimicrobial Agents and Chemotherapy (2 papers)Clinical Pharmacology & Therapeutics (2 papers)Proceedings of the National Academy of Sciences (2 papers)British Journal of Clinical Pharmacology (1 paper)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Mark Laughlin
34 papers receiving 2.5k citations
Mark Laughlin's Hit Papers
Peers
Comparison fields: 5 of 107
- Virology 755
- Infectious Diseases 1.3k
- Epidemiology 855
- Pharmacology 350
- Neurology 144
Countries citing papers authored by Mark Laughlin
This map shows the geographic impact of Mark Laughlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Laughlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Laughlin more than expected).
Fields of papers citing papers by Mark Laughlin
This network shows the impact of papers produced by Mark Laughlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Laughlin. The network helps show where Mark Laughlin may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Laughlin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Inhibition of Entry of HIV-1 in Neural Cell Lines by Antibodies Against Galactosyl Ceramide Hit paper breakdown → | 1991 | 475 |
| 2 | 2003 | 292 | |
| 3 | 2003 | 269 | |
| 4 | 1989 | 268 | |
| 5 | 2008 | 218 | |
| 6 | 2004 | 177 | |
| 7 | 2005 | 174 | |
| 8 | 2004 | 128 | |
| 9 | 2005 | 109 | |
| 10 | 2007 | 99 | |
| 11 | 1993 | 64 | |
| 12 | 1989 | 56 | |
| 13 | 1994 | 42 | |
| 14 | 1996 | 40 | |
| 15 | 2003 | 38 | |
| 16 | 1978 | 34 | |
| 17 | 1995 | 32 | |
| 18 | 1991 | 21 | |
| 19 | 2006 | 15 | |
| 20 | 2012 | 13 |
About Mark Laughlin
Mark Laughlin is a scholar working on Infectious Diseases, Virology, Molecular Biology, Pharmacology and Epidemiology, having authored 35 papers that have together received 2.6k indexed citations. Recurring topics across this work include HIV Research and Treatment (10 papers), Antifungal resistance and susceptibility (6 papers), Cholinesterase and Neurodegenerative Diseases (5 papers), HIV/AIDS Research and Interventions (5 papers), Alzheimer's disease research and treatments (4 papers), Pharmacogenetics and Drug Metabolism (4 papers), Ion Transport and Channel Regulation (3 papers) and Computational Drug Discovery Methods (3 papers). The work is most often cited by research in Virology (755 citations), Infectious Diseases (1.3k citations), Epidemiology (855 citations), Pharmacology (350 citations) and Neurology (144 citations). Mark Laughlin has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Josephine Lim, Rachel Courtney, Francisco González‐Scarano, Janet M. Harouse, David Wexler, Elaine Radwanski, Shama Bhat, Steven L. Spitalnik, Donald H. Silberberg and Vijay Batra. Their work appears in journals such as Alzheimer s & Dementia, Antimicrobial Agents and Chemotherapy, Clinical Pharmacology & Therapeutics, Proceedings of the National Academy of Sciences and British Journal of Clinical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.